PDF(Pubmed)
Abstract：
(1) Background: The purpose of this study was to determine whether the drooling of adult patients with diverse central nervous system diseases can be treated with botulinum toxin type A. (2) Methods: The Cochrane Library, MEDLINE, and Embase were all searched for studies that fit the inclusion criteria. The patients in the studies had to be adults (>18 years old), and the studies had to be randomized placebo-controlled trials, controlled trials, or prospective studies. Each study had to have enough quantifiable data available for meta-analysis. The primary outcome measure was the Drooling Severity and Frequency Scale (DSFS). (3) Results: The meta-analysis comprised three studies. A statistically significant difference in DSFS score between the treatment and control groups was observed in the meta-analysis, with an overall standardized mean difference of -0.9377 (95% CI, -1.2919 to -0.5836; p < 0.0001). A total of seven studies were ineligible for inclusion in the meta-analysis and were only assessed as qualitative data. All qualitative studies showed a significant reduction in DSFS score a few weeks or months after the injection of botulinum toxin. (4) Conclusions: Botulinum toxin type A is safe and effective as a treatment for drooling in adult patients with central nervous system diseases.
摘要：
（1）背景：本研究的目的是确定是否可以用A型肉毒杆菌毒素治疗患有多种中枢神经系统疾病的成年患者的流口水。（2）方法：Cochrane图书馆，MEDLINE,和Embase均搜索符合纳入标准的研究.研究中的患者必须是成年人（>18岁），这些研究必须是随机的安慰剂对照试验，对照试验,或前瞻性研究。每个研究都必须有足够的可量化数据可用于荟萃分析。主要结果测量是流口水严重程度和频率量表（DSFS）。（3）结果：荟萃分析包括三项研究。meta分析中观察到治疗组与对照组的DSFS评分差异有统计学意义。总体标准化平均差为-0.9377（95%CI，-1.2919至-0.5836；p<0.0001）。共有7项研究不符合纳入荟萃分析的条件，仅作为定性数据进行评估。所有定性研究均显示，在注射肉毒杆菌毒素后几周或几个月，DSFS评分显着降低。(4)结论:A型肉毒毒素治疗成人中枢神经系统疾病患者流口水是安全有效的。
